Clinical trials: Malignant Neoplasm of Prostate
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration Resistant Prostate Cancer (mCRPC)
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT07285694
- Testing
- AB-3028
- Where
- 9 sites in United States
- Volunteers
- 190 people
- Sponsor
- Arsenal Biosciences, Inc.
Locally Advanced or Metastatic Prostate Cancer.
Depiction of Prostate Cancer Treatment Alternatives in Greece
A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed…
- Trial name
- NCT00733213
- Where
- 4 sites in Greece
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Prostate Cancer, Prostatic Neoplasms
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01450683
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Abiraterone is approved in the United States by the U.S. Food and Drug Administration (FDA) to treat metastatic prostate cancer at 1000 mg daily.
- Trial name
- NCT02415621
- Testing
- Abiraterone Acetate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy)
Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial
The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy), Prostate Cancer Surgery, Prostate Cancers
- Trial name
- NCT06915909
- Testing
- surgery
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- East and North Hertfordshire NHS Trust
Prostate Cancer
Study of SU11248 in Men With Advanced Prostate Cancer
There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
- Trial name
- NCT00299741
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Bone Health Observational Study
Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced…
- Trial name
- BHOS (NCT00632905)
- Where
- 40 sites in Canada
- Volunteers
- 599 people
- Sponsor
- CMX Research
Prostate Carcinoma, Prostate Neoplasm
Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.
The AirSeal platform has been evaluated in urological surgeries, mainly in cases of malignant diseases 5,6. However, there is still a lack of data demonstrating the possible benefits of its use, which justifies the conduct of…
- Conditions
- Prostate Carcinoma, Prostate Neoplasm, Pain Intensity Assessment, Quality of Life (QOL)
- Trial name
- ARCO2 (NCT06784986)
- Testing
- The Conventional Insufflation System, AirSeal® System
- Where
- 2 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Brazilian Institute of Robotic Surgery
Urological Malignancies, Prostate Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles.
- Conditions
- Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer
- Trial name
- NCT04625556
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Prostate Cancer, Neoplasm Metastasis
BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00337155
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Bayer
Prostate Neoplasm
PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?
This evaluates the detection rates of prostate cancer by MRI-targeted prostate biopsy compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsy.
- Trial name
- PRECISION (NCT02380027)
- Testing
- MRI, MRI-targeted biopsy, TRUS-biopsy
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College, London
Prostate Cancer
An Open Label Prostate Cancer Study in Japanese Patients
The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action.
- Trial name
- NCT01351688
- Testing
- AZD3514
- Where
- 2 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Prostatic Neoplasm, Adenocarcinoma
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals.
- Conditions
- Prostatic Neoplasm, Adenocarcinoma, Neoplasm Recurrence, Neoplasm Metastasis
- Trial name
- KP-CARAIBES (NCT06046131)
- Testing
- Standard care
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Prostate Cancer
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
- Trial name
- NCT00841113
- Testing
- Abarelix, Goserelin plus Bicalutamide
- Volunteers
- 177 people
- Sponsor
- Speciality European Pharma Limited